 Home > Biochemistry News > Biotechnology News > 100% disease control rate in patients with pancreatic and gastrointestinal cancers with positive KRAS inhibitor Phase 2 results

100% disease control rate in patients with pancreatic and gastrointestinal cancers with positive KRAS inhibitor Phase 2 results

 Last Update: 2022-02-19
 Source: Internet
 Author: User

Tags

lab safety supply

cd 1 2

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Mirati Therapeutics announced today that its KRAS G12C inhibitor adagrasib has achieved positive results in a Phase 2 clinical trial called KRYSTAL-1

Adagrasib is a highly specific and potent oral KRAS G12C inhibitor optimized for durable target inhibition

▲Design features of Adagrasib (Image source: Mirati's official website)

The test results show:

As of September 10, 2021, the objective response rate (ORR) among evaluable patients (n=27) was 41% and the disease control rate (DCR) was 100%

The median progression-free survival (mPFS) was 6.

Adagrasib was well tolerated and had a manageable safety profile

References:

[1] Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

100% disease control rate in express pancreatic cancer and gastrointestinal cancer patients, positive phase 2 clinical results of KRAS inhibitor

02-21

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

100% disease control rate in patients with pancreatic and gastrointestinal cancers with positive KRAS inhibitor Phase 2 results

Related Articles

100% disease control rate in express pancreatic cancer and gastrointestinal cancer patients, positive phase 2 clinical results of KRAS inhibitor